




Acceleron is a privately-held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel protein therapeutics for orphan diseases and cancer

Acceleron's scientific approach takes advantage of its unique insight to discover first-in-class therapies based on the TGF- β protein superfamily. Acceleron utilizes proven biotherapeutic technologies and capitalizes on the company's internal GMP manufacturing capability to advance its therapeutic programs rapidly and efficiently.

Product Pipeline



[†] In Collaboration with Celgene Corporation

[‡] In Collaboration with Shire plc

[§] In Collaboration with Alkermes Inc.

4 Internally Discovered and Developed Products Entered Clinical Trials in 5 Years

Sotatercept (ACE-011)

Sotatercept (formerly called ACE-011) is an investigational protein therapeutic that increases red blood cell (RBC) levels by targeting molecules in the TGF- β superfamily. Acceleron is developing sotatercept in collaboration with Celgene Corporation for the treatment of anemia caused by chemotherapy and chronic kidney disease.

ACE-031

ACE-031 is an investigational protein therapeutic that increases skeletal muscle by preventing growth inhibitors from interacting with receptors on muscle cells called activin type IIB receptors (ActRIIB). Acceleron is developing ACE-031 in collaboration with Shire for treatment of Duchenne muscular dystrophy (DMD).

ACE-041

ACE-041 is an investigational protein therapeutic that inhibits angiogenesis by targeting the activin receptor-like kinase 1 (ALK1) pathway. Acceleron is developing ACE-041 for the treatment of patients with advanced cancer who have failed prior therapy.

ACE-536

ACE-536 is an investigational protein therapeutic that increases red blood cell (RBC) levels by targeting molecules in the TGF- β superfamily. Acceleron and Celgene are developing ACE-536 to treat anemia in patients with rare blood disorders.



Investors

Advanced Technology Ventures
Alkermes
Bessemer Ventures
Celgene
Flagship Ventures
MPM BioEquities
OrbiMed Advisors
Polaris Venture Partners
QVT Financial
Sutter Hill Ventures
Venrock

Board of Directors

Anthony B. Evin, Ph.D.
General Partner, Venrock
Associates

Jean George
General Partner, Advanced
Technology Ventures

Carl Gordon, Ph.D.
General Partner, OrbiMed
Advisors

Edwin M. Kania, Jr.
Senior Managing Director &
Chairman, Flagship Ventures

John Knopf, Ph.D.
Co-founder and CEO, Acceleron

**Tom Maniatis, Ph.D. (Co-
Founder)**
Professor of Biochemistry &
Molecular Biophysics, Columbia
University

Terrance G. McGuire
Co-founder and Managing General
Partner, Polaris Venture Partners

Richard Pops (Lead Director)
Chief Executive Officer, Alkermes

**Wylie W. Vale, Ph.D. (Co-
Founder)**
Professor of Molecular
Neurobiology, The Salk Institute
for Biological Studies

Joseph S. Zakrzewski
Chief Executive Officer, Amarin

Management Team

Executive Officers

John Knopf, Ph.D. (Co-Founder): Chief Executive Officer

Matthew L. Sherman, M.D.: SVP and Chief Medical Officer

Kevin McLaughlin: SVP and Chief Financial Officer

John Quisel, Ph.D., J.D.: VP and General Counsel

Robert Steininger: SVP, Manufacturing

Steven Ertel: SVP, Corporate Development

Nancy Sullivan: VP, Operations

Senior Management

Kenneth Attie, M.D., VP, Medical Research

James Desiderio, Ph.D.: VP, Regulatory

Ravi Kumar, Ph.D.: VP, Cell Biology and Bioanalytical Development

Melissa Morandi: VP, Quality

Doug Pagán: VP, Finance

Christopher Rovaldi: VP, Program Management

Accomplishments

- Raised over \$100M in venture financing and secured an additional \$170M + from partnerships.
- Four internally discovered and developed molecules are now being studied in human clinical trials
- An integrated drug discovery, development and manufacturing organization continues to advance numerous preclinical and clinical stage programs
- A robust product pipeline with several promising programs that modulate the growth of red blood cells, bone, muscle, and the vasculature
 - ACE-011 for Anemia
 - Entered into a collaboration with Celgene Corporation for worldwide development and commercialization
 - Initiated Phase 2/3 clinical trial in advanced lung cancer patients with chemotherapy-induced anemia and Phase 2 trial in patients with renal anemia
 - ACE-031 for Duchenne Muscular Dystrophy
 - Entered into a collaboration with Shire plc for development and commercialization in markets outside North America
 - Initiated Phase 2 clinical trial in Duchenne Muscular Dystrophy
 - ACE-041 for Advanced Cancer
 - Initiated Phase 1 clinical trial in patients with advanced cancer
 - Plans underway to initiate Phase 2 clinical trial in 2011
 - ACE-536 for Anemia
 - Entered into a collaboration with Celgene Corporation for worldwide development and commercialization
 - Initiated Phase 1 clinical trial